Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy
NCT04530552Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2021
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by National Cancer Institute. Started Jul 2021; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04530552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530552.